Quality, Safety and GMP for Advanced Therapy Medicinal Products (ATMPs)
10/11 November 2020 | Neuss/Düsseldorf, Germany

Highlights
- European and US Guidelines and Regulatory Requirements and Inspections
- Quality and Manufacturing of CAR-T-Cells
- GMP Implementation in University and Industry – Large Scale and Small Scale
- How to Handle Out-of-Specification Batches
- Microbiological Safety and Testing
- Approaches for Small Batches and Optimising Manufacturing

Speakers

Dr Hans-Georg Eckert
Valicare

Dr Anette Jork
BioNTech

Dr Ilona Kalaszczyńska
Medical University of Warsaw

Dr Thomas Meindl
Labor LS

Dr Christoph Peter
BioNTech

Dr Christoph Prinz
Apceth

Dr Christianne Reijnders
The Dutch Health and Youth Care Inspectorate

Dr Ralf Sanzenbacher
PEI, German Federal Agency for Vaccines and Biomedicines

Mag. Gabriela Schallmeiner
Inspection Ready

Prof. Michael Schmitt
University Hospital Heidelberg

Dr Jan Schrooten
Antleron

Dr Astrid Schwantes
PEI, German Federal Agency for Vaccines and Biomedicines

Regulatory Requirements and Practical Implementation
Objective

This workshop provides a comprehensive overview of the current regulatory requirements for the development, manufacture and approval of Advanced Therapy Medicinal Products (ATMP). Representatives of regulatory authorities, experts from small-scale and large-scale production, QC laboratories and consultants will report on their practical experiences. From the construction of a new production facility to the introduction of a quality system and the final sterility test, all relevant topics directly related to ATMPs will be covered.

Background

Modern systems of regenerative medicines, especially ATMPs (gene therapeutics, somatic cell-based products and tissue-based products) represent an innovative group of drugs that is becoming increasingly important. With the introduction of several regulatory guidelines e.g. of the European Directive EC 1394/2007 for ATMP, such products were classified as medicinal products and must therefore comply as such with the EU requirements for medicinal products. Although the biopharmaceutical industry has considerably intensified its activities in this field, many of these products are developed and manufactured at universities, hospitals and in small- and medium-sized companies. These university or medical origins result in special challenges for the respective institutions as well as for the regulatory authorities in fulfilling the compliance requirements for quality, safety and GMP aspects and approval. This is also underlined by commonly occurring operating conditions, e.g. the open manipulation of cells and tissues, which are necessary for obtaining such products on a medical/surgical level or by the short shelf life of the obtained final product.

This results in a whole range of extraordinary requirements:
- the consideration of later requirements during development and in clinical phases
- the implementation of quality assurance requirements during aseptic production
- the use of alternative methods for analysis and microbiological control and the demonstration of comparability with conventional methods
- the handling of out of specification (OOS) / out of limit (OOL) results during product testing and the possibility of batch release

Target Audience

This seminar is aimed at all persons who
- Are involved in basic or translational research on cell-based therapy concepts with the perspective of clinical application
- Are involved in the extraction and manufacture of cells, tissues and ATMPs
- Are responsible for quality assurance and control of cells, tissues and ATMPs
- Are responsible for microbiological or analytical testing
- Perform inspections or audits of ATMP facilities
- Are responsible for GMP requirements during pre-approval phases
- Deal with authorisation

Programme

**Programme**

**Regulatory Development**
- New and revised guidelines
- Other relevant documents
- Current experiences and expectations

**Challenges for Cell-Based Medicinal Products**
- How to increase stability of cell-based medicinal products
- Can growth medium influence properties of cell-based medicinal product

**Risk-based Approach and Evaluation is the Leading Tool towards Manufacturing Authorization for iATMPs**
- European GMP guideline Part IV: GMP for ATMPs
- Gaining flexibility by professional risk reduction
- Time to manufacturing authorization

**Cell by Design®, a Quality-Focused Process Development Roadmap for ATMPs**
- Software for risk-based ATMP process development and data driven decision making
- Quality by design principles coupled to ATMP legislations, standards and guidelines
- Master quality, manufacturability and scalability of ATMP product and process
- Enable QC cost-effectiveness by parametric release

**A Case Study - Optimizing Manufacturing**
- Patient individualized cancer treatment using targeted RNAs
- The challenges of patient individualized medicines
- The challenge of small batches in combination with large batch numbers
- How to establish high throughput manufacturing - dos and don’ts

**In-house Production of CAR-T Cells**

**ATMP Challenges for a QP**
- A glimpse on the legal framework
- The complexity
- ATMP specific challenges
- What you should know about working with a QP

**ATMP GMP Inspection Experiences**
- Findings
- Pitfalls
- Hospital exemption
Strategies for Validating Nucleic Acid-based Techniques for Testing for the Absence of Mycoplasma

- NAT Techniques
- Strategies for validation/suitability tests
- Pitfalls and practical examples

Virus Safety Concepts for ATMPs

- Safety of raw and starting materials
- Serum and serum replacement(s) for cell-based products
- Testing methodologies (NGS)
- Virus inactivation and removal

Process Optimization for Individualized ATMPs - a Modern Approach

- Aseptic filling for small batches
- Hygiene monitoring in closed isolators required?
- Regulatory challenges

Treating Patients with OOS Batches - when Physicians Request Non-Conforming ATMPs

- Regulatory framework
- Perspective and expectations from patients, physicians, sponsors, manufacturers, QPs, authorities - EU vs. US
- Batch control, review and release process

Moderator
Dr Andrea Hauser, Vice Chair ECA ATMP Interest Group, University Hospital Regensburg

Speakers

Dr Hans-Georg Eckert, Valicare GmbH, Germany
Dr Eckert is biologist by education and has more than 20 years of professional experience in accompanying and managing compliance tasks. After positions as Project Manager and Head of Quality, he has led Valicare since 2016 as Site Manager with special focus on ATP-GMP projects.

Dr Annette Jork, BioNTech, Germany
Dr Jork works as a Qualified Person for BioNTech since 2018. From 2001 to 2017 she worked for BTG International GmbH/CellMed AG in different functions e.g. Head of QC, QP and Director of Quality. She gained additional international experience in QM as part of her secondments from 2014 to 2017 in the UK and the US.

Dr Ilona Kalaszczyńska, Medical University of Warsaw
Ilona Kalaszczyńska is a graduate of the Faculty of Biology at the University of Warsaw. Since 2010, she is an associate professor at the Medical University of Warsaw. Since 2014, participated in or directed the process of accreditation of several cell/tissue banks - cord blood, bone allografts, and stem cell-based ATMPs. In 2016 she became a Quality Control Manager at the Laboratory for Cell Research and Application of the Medical University of Warsaw.

Dr Thomas Meindl, Labor LS, Germany
Dr Meindl has been head of the Labor L+ S AG division since 2005. From 2003 to 2005 he worked in oncolgical research at SKM Oncology GmbH. Prior to that, Dr Meindl was project manager at Sym pore where he was responsible for the development of new and modified drugs.

Dr Christoph Peter, BioNTech, Germany
Dr. Peter studied at the University of Heidelberg and gained his PhD at the Max-Planck Institute for Medical Research. After a postdoc fellowship at Stanford University, he joined Apeth, a CMO for cell based ATMPs in 2008 as Head of Production. 2011 he became Deputy QP and later Head of Quality Assurance. 2016 he came to BioNTech as Head of Quality and Deputy Qualified Person.

Dr Christoph Prinz, Apeth, Germany
Dr Prinz is pharmacist and joined Novartis as Critical Deviation Investigator in 2011 before he changed to apceth Biopharma. Parallel to his work in the pharmaceutical development of new stem-cell based ATMPs, he increasingly took over responsibility in Quality Management. In 2018, he became Head of Quality Management and Qualified Person responsible for investigational and commercial ATMPs.

Dr Christianne Reijnders, The Dutch Health and Youth Care Inspectorate
Christianne studied at the University of Utrecht Medical Biology and gained her PhD at the VU University Medical Centre (The Netherlands). Following she worked at the Leids University Medical Centre and at A-Skin Nederland B.V. In 2017 she became Senior Inspector at the Dutch Health and Youth Care Inspectorate (Netherlands) for GMP inspections.

Dr Ralf Sanzenbacher, Paul-Ehrlich-Institut, German Federal Institute for Vaccines and Biomedicines
Dr Sanzenbacher works at the Section of Somatic Cell Therapy and Tissue Engineering at the Paul-Ehrlich-Institut. He is an expert for regulatory aspects, as well as quality and preclinical issues aspects within the scope of manufacturing license, clinical trials and marketing authorisation. He is also member of several expert panels on cell therapies.

Prof Dr Michael Schmitt, University Clinic and University of Heidelberg, Germany
Michael Schmitt obtained his MD from the University of the Saarland, Homburg, Germany. He is currently Siebeneicher-Endowment Professor of Cellular Immuno-therapy and Head of the Good Manufacturing Practice (GMP) Facility at the University Clinic Heidelberg, Germany.

Dr.ir. Jan Schrooten, Antleron, Belgium
Antleron is a young R&D company on a mission to enable personalized manufacturing 4.0 in the domain of advanced therapies. Previously Jan Schrooten was senior research manager at KU Leuven (Belgium), responsible for the long-term management and technology transfer of biomaterials and tissue engineering research.

Dr Astrid Schwantes, Paul Ehrlich Institut, Federal Institute for Vaccines and Biomedicines
Dr Schwantes studied Biology at the University Mainz. 2003 she joined the Division of Virology at the Paul-Ehrlich Institut. Since 2013 she is regulatory assessor at the section virus safety at the PEI.
General terms and conditions
If you cannot attend the conference you have two options:
1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely we must charge the following processing fees:
   - Cancellation until 2 weeks prior to the conference 10 %,
   - Cancellation until 1 week prior to the conference 50 %,
   - Cancellation within 1 week prior to the conference 100 %.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event. In case the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of invoice. Important: This is a binding registration and fees are due in case of cancellation or non-appearance. You have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message.
In case you do not appear at the event without having informed us, you will have to pay the full registration fee even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will be confirmed)! (As of January 2012).

German law shall apply. Court of jurisdiction is Heidelberg.

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.

---

**Reservation Form (Please complete in full)**

**Quality, Safety and GMP for Advanced Therapy Medicinal Products (ATMPs)**

**10/11 November, Neuss/Düsseldorf, Germany**

**Title, first name, surname**

**Department**

**Company**

**Important: Please indicate your company’s VAT ID Number**

**Purchase Order Number, if applicable**

**City**

**ZIP Code**

**Country**

**Phone / Fax**

**E-Mail (Please fill in)**

---

**CONCEPT HEIDELBERG**

P.O. Box 101764

Fax +49 (0) 62 21/84 44 34

D-69007 Heidelberg

GERMANY

---

For questions regarding reservation, hotel, organisation etc. please contact:

Mr. Niklaus Thiel (Organisation Manager) at

+49(0)62 21/78 44 44 or at

thiel@concept-heidelberg.de.

---

**Conference language**

The official conference language will be English.

**ECA Members** €1,590

**APIC Members** €1,690

**Non-ECA Members** €1,790

**EU GMP Inspectorates** €895

**Academic Scientists/Students** €895

**ECA Members** €1,590

**APIC Members** €1,690

**Non-ECA Members** €1,790

**EU GMP Inspectorates** €895

**Academic Scientists/Students** €895

**The conference fee is payable in advance after receipt of invoice and includes conference documentation, dinner on the first day, lunch on both days and all refreshments. VAT is re-